NuVasive — Q1 2018 Earnings Presentation
15 slides from NuVasive's earnings presentation, May 1, 2018
Slide 1: Q1 2018 Results Supplemental Presentation to Earnings Press Release
Q1 2018 Results Supplemental Presentation to Earnings Press Release May 1, 2018 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, one-time restructuri
Slide 4: Q1 2018 Financial Performance
Q1 2018 Financial Performance GAAP diluted loss per share of ($0.53) and non-GAAP diluted EPS of $0.39, up 5.4% despite softness in U.S. market GAAP operating profit margin of (7.0%) and non-GAAP operating profit margin of 12.3% Increased revenue of $260.5M, up 4.6% over prior year Strong Internatio
Slide 5: Q1 2018 Revenue Drivers
Q1 2018 Revenue Drivers Revenue (in millions) Q1 2018 Growth Rate Q1 2018 v. Q1 2017 Key Performance Factors U.S. Spinal Hardware Includes all Implants, Fixation & NuVasive Specialized Orthopedics (NSO) $141.5 1% Growth in case volume of ~5%, and contributions from new product introductions, offset
Slide 6: Non-GAAP Measures
Non-GAAP Measures 1Q18 Actuals 1Q18 YoY Performance Factors Gross Margin 71.8% 350 bps below prior year of 75.3%. The variance to prior year was primarily driven by slower production throughput at our West Carrollton facility, the addition of SafePassage and stronger mix of the International busines
Slide 7: The Leader in Lateral. Lateral Single-Position Surgery.
The Leader in Lateral. Lateral Single-Position Surgery. XLIF Lateral ALIF XLIF Crestline Lateral MAS Fixation 2018 Disruptive Technology 7
Slide 8: Leading Innovation with Advanced Materials Science
Leading Innovation with Advanced Materials Science™ SURFACE IMAGING STRUCTURE MODULUS PROPRIETARY POROUS TITANIUM COHERE and COALESCE PROPRIETARY POROUS PEEK™ 2018 Disruptive Technology 8
Slide 9: Surgical Intelligence. Our Roadmap of Innovation.
Neuromonitoring 01 PHASE Surgical Planning 02 PHASE Radiation Reduction 03 PHASE Navigation & Imaging 04 PHASE Cloud Integration & Data Connectivity 05 PHASE Data Insights & Smart Tools 06 PHASE Data & Clinical Insights Surgical Intelligence™. Our Roadmap of Innovation. 2018 Disruptive Technology 9
Slide 10: Building Out NUVA International Platform
Strategy to more than double the International business over next five years at ~35% non-GAAP operating margins. International Revenue (Constant Currency*, In Millions) ~27% CAGR 10 * Constant currency based on 2017 rates. Building Out NUVA International Platform 4.5% INTERNATIONAL MARKET SHARE - SI
Slide 11: Reiterating 2018 Full-Year Guidance
$1,095M – $1,105M Full-Year Non-GAAP Operating Profit Margin Full-Year Revenue ~17.6% Full-Year Non-GAAP EPS $2.44 - $2.47 * NuVasive financial performance guidance as of May 1, 2018, inclusive of SafePassage (closed January 2018). All prior year financial information has been re-casted and presente
Slide 12: 2018 Guidance Assumptions Unchanged
CONTRIBUTORS TO REVENUE GROWTH International revenue continues to grow 20%+ New product launches in 2H’17 ramp throughout the year In-sourced manufacturing efforts become significantly accretive in 2H’18 Biologics remains pressured for near-term U.S. spine procedural volumes relatively flat NUVASIVE
Slide 13: 2018 Full-Year Financial Performance Guidance
* NuVasive financial performance guidance as of May 1, 2018, inclusive of SafePassage (closed January 2018). All prior year financial information has been re-casted and presented based on our full retrospective method of adoption of ASC 606 2018 Full-Year Financial Performance Guidance* Financial Me
Slide 14: Steady Progress Against Investment Thesis
Steady Progress Against Investment Thesis RELENTLESS FOCUS ON DRIVING SHAREHOLDER VALUE International revenue growth 20%; slower than expected U.S. growth, but still growing multiples of the market and taking share. Remain committed to annual 100 bps of non-GAAP op margin expansion; slower U.S. mark
Slide 15: Slide 15